Showing results (51-60 of 4,789) with videos related to
Sort By:
Pageof 479
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 3, 2009
Earlier disability of the patients followed in Multiple Sclerosis centers compared to outpatientsM Debouverie, L Laforest, E Van Ganse, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|February 3, 2009
Longitudinal correlates of fatigue in multiple sclerosisE Patrick, C Christodoulou, L B Krupp, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|October 12, 2010
Increasing incidence of multiple sclerosis in women in Northern FinlandO Krökki, R Bloigu, M Reunanen, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|October 12, 2010
Interferon-beta is a key regulator of proinflammatory events in experimental autoimmune encephalomyelitisC L Galligan, L M Pennell, T T Murooka, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|November 3, 2010
Extracranial venous stenosis is an unlikely cause of multiple sclerosisBassem Yamout, Aline Herlopian, Zeinab Issa, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|June 8, 2019
Psychological resilience is linked to motor strength and gait endurance in early multiple sclerosisSylvia Klineova, Rachel Brandstadter, Michelle T Fabian, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|June 8, 2019
Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trialsGiancarlo Comi, Aaron E Miller, Myriam Benamor, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|June 21, 2019
Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trialMelissa Cambron, Jop Mostert, Marie D'Hooghe, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|June 21, 2019
Modifiable risk factors for poor health outcomes in multiple sclerosis: The urgent need for research to maximise smoking cessation successClaudia H Marck, Roshan das Nair, Lisa B Grech, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|June 22, 2019
A pharmacogenetic study implicates NINJ2 in the response to Interferon-β in multiple sclerosisSilvia Peroni, Melissa Sorosina, Sunny Malhotra, et al.Pageof 479